Grace Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Grace Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-127,729	Closed	-$2.3M	–	249
2020 Q2	$2.3M	Sell	127,729 -147,103	-54%	-$2.05M	1.97%	8
2020 Q1	$1.96M	Buy	274,832 +4,000	+1%	+$49.9K	1.93%	10
2019 Q4	$6.47M	Sell	270,832 -40,300	-13%	-$1.11M	5.27%	3
2019 Q3	$8.35M	Sell	311,132 -8,000	-3%	-$225K	8.43%	2
2019 Q2	$8.66M	Sell	319,132 -3,000	-0.9%	-$94.1K	4.13%	2
2019 Q1	$11.2M	Buy	322,132 +42,923	+15%	+$1.24M	4.36%	2
2018 Q4	$5.46M	Buy	279,209 +125,480	+82%	+$2.58M	2.53%	4
2018 Q3	$4.09M	Hold	153,729	–	–	1.6%	13
2018 Q2	$5.81M	Buy	+153,729	New	+$5.88M	2.22%	7

Grace Capital's PTLA Position: Q3 2020 in Review

Grace Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 127,729 shares — an estimated $2.3M sold.

Grace Capital first reported a position in PTLA in Q2 2018 and held it in 9 quarters. The position peaked at $11.2M in Q1 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Grace Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Grace Capital sold 127,729 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $2.3M.
Grace Capital first reported a position in Portola Pharmaceuticals, Inc. in Q2 2018 and held it in 9 quarters.
Grace Capital's Portola Pharmaceuticals, Inc. position peaked at $11.2M in Q1 2019.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Grace Capital's 13F filing for Q3 2020, filed 12 Nov 2020.